AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

Other researchers have also been studying mixing vaccine types to fight COVID-19. A Spanish study recently reported that people who initially received the AstraZeneca vaccine experienced a massive ...

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

finds bombshell new study into the origin of the global pandemic "This has led to a decline in demand for Vaxzevria, which is ...

The study, published in Nature Communications ... the wide uptake of future COVID-19 vaccination programs. In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria ...

a UK study has found. The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the ...

A new SERD molecular entity, camizestrant, is under clinical development by biopharmaceutical company AstraZeneca and is currently in a Phase III study. The drug candidate is administered orally ...

Giving people the tools to do their job more effectively has boosted productivity at AstraZeneca ... the benefits of this evolution in a case study video produced by Veeva. She said: “We ...

The Pfizer and AstraZeneca coronavirus vaccines are highly effective against the variant identified in India after two doses, a study has found. Two jabs of either vaccine give a similar level of ...

AstraZeneca (NASDAQ:AZN ... today at the European Society for Medical Oncology (ESMO) Congress 2024. The study, which examined the STRIDE regimen (Single Tremelimumab-actl Regular Interval ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.